Share
430 Posts.
lightbulb Created with Sketch. 100
clock Created with Sketch. 26/08/19
23:46
Share
Originally posted by Red bar
↑
Remember in the SmartCough-C2 announcement results published the company stated that they will be applying for a "phase 2" for pneumonia and bronchitis, I think that's how they put it... so they will be presenting a case to the FDA later for pneumonia and bronchitis as they don't want to complicate the matter now with the respiratory infections that are passable.. However is it really necessary? If the algorithm can determine if you have an upper or lower respiratory tract infection than that information should be all one really requires... it's a bonus that it is also very accurate at distinguishing cough signatures for asthma too.. If you have an upper respiratory tract infection it's not a serious problem, if you have a lower respiratory tract infection it is very serious and requires urgent medical care... perhaps our company will run a small timescale study on this in a third round in conjunction with the adult trials over in the United States and potentially another one on croup... I'm expecting the adult US study results to be nothing short of outstanding, especially after they now have had two attempts to get it right with kids, they should know the US hospital system back to front by now, the data set will be trained and tailored for US patience and the algorithm is always improving with the more data it receives. I believe enrolment will commence this coming US Winter it will be interesting to see how the company structures the study this time and if they go with three adjudicators like they did before.
Expand
From the Ann ‘ The clinical diagnosis was made by a clinical adjudication committee using all available clinical data, including radiology and microbiology. https://www.resapphealth.com.au/res...ralian-prospective-paediatric-clinical-study/ “when compared to a diagnosis reached by a panel of paediatricians after they had reviewed hospital charts and conducted all available clinical investigations. https://www.resapphealth.com.au/breathe-easy-paediatric-study-published-in-peer-reviewed-journal/ Not investment advice, do your own research, and consult a licensed adviser.
